T cell activation

Discover the groundbreaking findings from a study on bispecific T cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. Download this Case Study to […]

Discover the groundbreaking findings from a study on bispecific T-cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. What you will learn: The correlation […]

New research in mice has identified how gut bacteria alter the body’s response to PD-1 checkpoint blockade immunotherapy, currently used for the treatment of 25 forms of cancer. The findings could inform the design of treatments that boost the efficacy of cancer immunotherapy among patients with suboptimal response. The research by investigators at Harvard Medical […]

Patients with relapsed or refractory multiple myeloma who were treated with the two highest doses of REGN5459, a bispecific antibody targeting BCMA and CD3, experienced a 90.5% overall response rate. This is according to results of a Phase I/II clinical trial presented at the AACR Annual Meeting 2023 in Florida. REGN5459 binds to BCMA on […]

Sonoma Biotherapeutics and Regeneron Pharmaceuticals have announced plans to collaborate on the discovery, development and commercialisation of novel regulatory T cell (Treg) therapies for autoimmune diseases. The collaboration will bring together Regeneron’s VelociSuite technologies for the discovery and characterisation of fully human antibodies and T cell receptors (TCRs) with Sonoma Biotherapeutics’ approach to developing and […]

New findings suggest that the SARS-CoV-2 virus damages an important immune-cell response. The quality of CD8+ T cell response to two doses of the Pfizer-BioNTech Covid-19 vaccine was considerably lower in people with prior SARS-CoV-2 infection compared to people without prior infection, the US study found. In addition, the level of this T cell was […]

Scientists at the Francis Crick Institute have found that high consumption of a common artificial sweetener, sucralose, lowers activation of T cells in mice. If found to have similar effects in humans, one day it could be used therapeutically to help dampen T cell responses. For example, in patients with autoimmune diseases who suffer from […]

DDW’s Diana Spencer reports on the recent Avacta Therapeutics Science Day, which explored the latest exciting developments in precision and targeted treatments for cancer and asked what advances the future might bring. The Avacta Therapeutics Science Day brought together senior company scientists and international oncology experts to provide an overview of the current development of […]

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial.  The AELIX-003 trial evaluated the safety, tolerability, immunogenicity and efficacy of AELIX’s HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7) agonist, vesatolimod (VES), in people with HIV on […]

A Phase I safety and pharmacodynamic activity trial shows IMC-M113V, the first soluble T cell receptor (TCR) therapy for people living with HIV, is well tolerated.  Immunocore presented the findings at the Conference on Retroviruses and Opportunistic Infection (CROI).  The bispecific soluble TCR therapy built on the company’s ImmTAX technology which is being developed for […]